Clinically, PELP-1 has been found to be an independent prognostic predictor of breast cancer-specific and disease-free survival [15] and has also been shown to be a marker associated with tamoxifen resistance, with patients whose tumours had high levels of cytoplasmic PELP1 responding poorly to treatment [16]. This evidence concerns the gene PELP1 and neoplasm.